Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,042 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.
Simpson EL, Imafuku S, Poulin Y, Ungar B, Zhou L, Malik K, Wen HC, Xu H, Estrada YD, Peng X, Chen M, Shah N, Suarez-Farinas M, Pavel AB, Nograles K, Guttman-Yassky E. Simpson EL, et al. Among authors: malik k. J Invest Dermatol. 2019 May;139(5):1063-1072. doi: 10.1016/j.jid.2018.10.043. Epub 2018 Dec 5. J Invest Dermatol. 2019. PMID: 30528828 Free article. Clinical Trial.
Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis.
Guttman-Yassky E, Ungar B, Malik K, Dickstein D, Suprun M, Estrada YD, Xu H, Peng X, Oliva M, Todd D, Labuda T, Suarez-Farinas M, Bissonnette R. Guttman-Yassky E, et al. Among authors: malik k. J Allergy Clin Immunol. 2017 Oct;140(4):1032-1042.e13. doi: 10.1016/j.jaci.2017.01.027. Epub 2017 Feb 24. J Allergy Clin Immunol. 2017. PMID: 28238742 Free article. Clinical Trial.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG. Guttman-Yassky E, et al. Among authors: malik k. J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17. J Am Acad Dermatol. 2018. PMID: 29353025 Free PMC article. Clinical Trial.
Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: A randomized controlled trial.
Czarnowicki T, Dohlman AB, Malik K, Antonini D, Bissonnette R, Chan TC, Zhou L, Wen HC, Estrada Y, Xu H, Bryson C, Shen J, Lala D, Ma'ayan A, McGeehan G, Gregg R, Guttman-Yassky E. Czarnowicki T, et al. Among authors: malik k. Ann Allergy Asthma Immunol. 2018 Jun;120(6):631-640.e11. doi: 10.1016/j.anai.2018.03.013. Epub 2018 Mar 19. Ann Allergy Asthma Immunol. 2018. PMID: 29567358 Clinical Trial.
Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures.
Wen HC, Czarnowicki T, Noda S, Malik K, Pavel AB, Nakajima S, Honda T, Shin JU, Lee H, Chou M, Estrada Y, Zheng X, Xu H, Krueger JG, Lee KH, Kabashima K, Guttman-Yassky E. Wen HC, et al. Among authors: malik k. J Allergy Clin Immunol. 2018 Jul;142(1):324-328.e11. doi: 10.1016/j.jaci.2018.02.047. Epub 2018 Apr 11. J Allergy Clin Immunol. 2018. PMID: 29653116 No abstract available.
The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood.
Czarnowicki T, He H, Leonard A, Malik K, Magidi S, Rangel S, Patel K, Ramsey K, Murphrey M, Song T, Estrada Y, Wen HC, Krueger JG, Guttman-Yassky E, Paller AS. Czarnowicki T, et al. Among authors: malik k. J Invest Dermatol. 2018 Oct;138(10):2157-2167. doi: 10.1016/j.jid.2018.03.1523. Epub 2018 Apr 14. J Invest Dermatol. 2018. PMID: 29660300 Free article.
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, Jim On S, Vekaria AS, Traidl-Hoffmann C, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Fuentes-Duculan J, Li X, Zheng X, Estrada Y, Garcet S, Wen HC, Gonzalez J, Coats I, Cueto I, Neumann AU, Lebwohl MG, Krueger JG, Guttman-Yassky E. Brunner PM, et al. Among authors: malik k. J Allergy Clin Immunol. 2019 Jan;143(1):142-154. doi: 10.1016/j.jaci.2018.07.028. Epub 2018 Aug 17. J Allergy Clin Immunol. 2019. PMID: 30121291 Clinical Trial.
Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.
Zhou L, Leonard A, Pavel AB, Malik K, Raja A, Glickman J, Estrada YD, Peng X, Del Duca E, Sanz-Cabanillas J, Ruano J, Xu H, Zhang N, Wen HC, Gonzalez J, Garcet S, Krueger JG, Guttman-Yassky E. Zhou L, et al. Among authors: malik k. J Allergy Clin Immunol. 2019 Jul;144(1):144-156. doi: 10.1016/j.jaci.2019.01.015. Epub 2019 Jan 24. J Allergy Clin Immunol. 2019. PMID: 30685456 Free article.
1,042 results